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Abstract
Objective. To develop an additive numerical scoring scheme for the BILAG-2004 index.
Methods. SLE patients were recruited into this multi-centre cross-sectional study. At every assessment,
data were collected on disease activity and therapy. Logistic regression was used to model an increase in
therapy, as an indicator of active disease, by the BILAG-2004 index score in the nine systems. As both
indicate inactivity, scores of D and E were set to 0 and used as the baseline in the fitted model. The models
were used to determine the numerical values for Grades A–C. Different scoring schemes were compared.
Results. There were 1510 assessments from 369 SLE patients. The coding schemes suggested for the
Classic BILAG index (A=12, B=5, C=1, D/E=0 and A=9, B=3, C=1, D/E=0) did not fit the data well.
A coding scheme (A=12, B=8, C=1 and D/E=0) was recommended, based on analysis results and
consistency with the numerical coding scheme of the Classic BILAG index.
Conclusion. A reasonable additive numerical scoring scheme based on treatment decision for the
BILAG-2004 index is A=12, B=8, C=1, D=0 and E=0.
Key words: SLE, Outcome measures, Disease activity, BILAG-2004, Statistics, Global score, Regression
model, Treatment decision.
Introduction
The BILAG-2004 index is a comprehensive composite
clinical index that has been recently validated for the
assessment of SLE disease activity [1–4]. This index is
based on the Classic BILAG index and has many simila-
rities with its predecessor: it is based on the principle of
the physician’s intention to treat, has transitional property
that captures changing severity of clinical manifestations
and has a similar ordinal scale scoring system. However, it
has nine systems and many of the changes (from the
Classic BILAG index) are in the items, glossary and scor-
ing scheme. As with the Classic BILAG index, the individ-
ual system scores were not intended to be summated into
a global score.
However, the accommodation of ordinal data and the
multiplicity of systems do limit statistical analyses. In sit-
uations where a single summary (numerical) measure for
the BILAG-2004 index is desirable, there is currently no
coding scheme available. We recently performed a formal
analysis to derive a numerical coding scheme for the
Classic BILAG index based on data from clinical practice
[5]. The numerical coding scheme for the Classic BILAG
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index due to the changes made during development.
We have performed a similar analysis to develop an
additive numerical scoring scheme for the BILAG-2004
index based on treatment decision. This analysis used
the same data set from which the numerical scoring of
the Classic BILAG index was derived, as data on the
BILAG-2004 index were available.
Patients and methods
The data for this cross-sectional analysis came from a
multi-centre study in the UK to validate the BILAG-2004
index that has been reported [3]. Details of the study have
been described previously [6]. In summary, patients with
SLE who satisfied the revised ACR criteria for classifica-
tion of SLE were recruited [7, 8]. At every assessment,
data on disease activity using the BILAG-2004 index
and treatment were collected. This study received multi-
centre research ethical approval from Hull and East Riding
Research Ethics Committee as well as approval from the
local research ethics committees of all participating cen-
tres. Written consent was obtained from all patients. This
study was carried out in accordance with the Declaration
of Helsinki.
BILAG-2004index
This is an ordinal scale index that has nine systems
(Constitutional, Mucocutaneous, Neuropsychiatric, Mus-
culoskeletal, Cardiorespiratory, Gastrointestinal, Ophthal-
mic, Renal and Haematological). Disease activity is
categorized into five levels, Grades A–E [4].
Following completion of the study, some issues with the
scoring scheme for the Haematological system were
noted. Through consensus of the BILAG, changes were
made to this scoring scheme, that were based on data
(data not shown), to improve the scoring system. These
changes only affected the Haematological system score
calculation and had no impact on data collection. The
modified Haematological scoring system was used in
this analysis. The revised index (BILAG-2004 index form,
glossary and scoring scheme—revision 1 September
2009) incorporating this change is available as supple-
mentary data at Rheumatology Online.
Change intherapy
Change in therapy has been chosen as the reference stan-
dard for disease activity and used as the response (out-
come) variable. This is based on the well-defined
benchmark for active disease, which is the decision to
treat and is in line with the previous study that derived
the scoring for the Classic BILAG index [6].
A robust definition for change in therapy was used,
similar to the definition used in our previous study [6].
Change in therapy was the change in treatment following
the assessment. The medications of interest included
immunosuppressives, anti-malarials, glucocorticoids,
biological therapy, topical glucocorticoids, topical
immunosuppressives, intravenous immunoglobulins,
plasmapheresis, anti-coagulation, prasterone, thalido-
mide and retinoids. NSAIDs were not included as they
are commonly used to treat non-lupus indications (espe-
cially for pain relief) and some could be obtained as non-
prescription medication. For this analysis, change in ther-
apy was categorized into ‘increase in therapy’ and ‘no
increase in therapy’.
Statistical analysis
All analyses were performed using R software (Vienna,
Austria) [9]. Logistic regression was used to relate the
probability of an increase in therapy (outcome variable)
to the counts of the BILAG-2004 index scores obtained
in each system (explanatory variables) at each assess-
ment. Grades D and E were combined for this analysis,
both indicating inactivity. Thus, four categorical scores
were possible (A–D).
What we term a total counts model is defined as
log P= 1   P ðÞ ðÞ ¼   þ  AxA þ  BxB þ  CxC þ  DxD
where P is the probability of an increase in therapy,   is
the intercept term and xA, xB, xC and xD are explanatory
variables representing the number of Grades A, B, C and
D/E scores, respectively, at each assessment.  A,  B,  C
and  D are the coefficients for the corresponding explan-
atory variables xA, xB, xC and xD.
Grade D/E, indicating inactivity, was used as the refer-
ence category in the model. As such, both Grades D and
E were implicitly assigned the numerical value of 0 (coef-
ficient  D for Grade D/E had a value of 0). The coefficients
for the other explanatory variables ( A,  B and  C) can be
estimated and used to derive the numerical values for
Grades A, B and C. Estimation was based on generalized
estimating equations with an independent working corre-
lation matrix to account for the correlation between mul-
tiple assessments from the same patient. This generated a
robust estimate for the variance matrix of the maximum
likelihood estimates. The ratios of the estimates of these
coefficients (denoted by ^  A, ^  B and ^  C), and their distri-
butions, provided a relative weighting of Grades A, B and
C, which was used in the formulation of possible numer-
ical values for Grades A, B and C.
A numerical global score would be the summation of
the numerical value for the nine-system scores, as given
by the following formula:
Numerical global scoreðxSÞ¼NAxA þ NBxB þ NCxC
where xA, xB and xC represent the number of Grades A, B
and C, respectively, at each assessment. NA, NB and NC
represent the numerical scores associated with Grades A,
B and C, respectively.
Various coding schemes were considered, including the
recommended (A=12, B=5, C=1 and D/E=0) and orig-
inal (A=9, B=3, C=1 and D/E=0) numerical scoring for
the Classic BILAG index [6]. Further logistic regression
models were used to determine how well these coding
schemes are compared with the total counts model.
These single-variable models were of the form:
logðP=ð1   PÞ¼ þ SxS
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the intercept term, xS is the numerical global score
obtained using a particular coding scheme and  S is the
coefficient for the numerical global score xS.
Wald tests on 2 degrees of freedom were used to exam-
ine whether there was a demonstrable difference in fit
between a single-variable model and the total counts
model. Comparable fits between the models indicate
that the weightings suggested in the coding scheme for
Grades A, B, C and D/E are consistent with the data.
Results
There were 369 SLE patients with 1510 assessments
available for analysis. Eighty-eight per cent of these
patients had more than one assessment during the
study period. An increase in therapy occurred in 22.6%
of the assessments. Patient demographics are summar-
ized in Table 1. Summaries of the individual assessment
BILAG-2004 index scores, for patients with and without an
increase in therapy, are given in Table 2.
The recommended (A=12, B=5, C=1 and D/E=0) and
original (A=9, B=3, C=1 and D/E=0) numerical scoring
scheme for the Classic BILAG index were assessed to
determine if they were applicable to the BILAG-2004
index. Using Wald tests, there was significant evidence
that both the recommended and original coding schemes
for the Classic BILAG index were not appropriate as they
did not fit the data as well as the total counts model
(P<0.001 for both). More specifically, for the analysis of
the recommended Classic BILAG index scoring scheme,
modification of the A score through the addition of the
variable xA was not significant (P=0.457), whereas the
addition of the B scores through xB was (P=0.022).
Thus, the numerical coding of 5 for Grade B may be
inappropriate.
Figure 1 presents simulated distributions of the maxi-
mum likelihood estimates of the Grade A to B (A/B) and
Grade A to C (A/C) scoring ratios from the total counts
model. The estimated A/B ratio is  1.5 and the ratio
from the recommended Classic BILAG index scoring,
12/5=2.4, is in the extreme upper tail of the distribution
and not supported by the data. In contrast, the estimated
A/C ratio is 19.7 but the Classic BILAG index value of
12 lies well within the lower tail at the 23rd percentile of
the distribution, consistent with the data.
Therefore, a suggested modification of the Classic
BILAG index scoring for use with the BILAG-2004 index
is A=12, B=8, C=1 and D/E=0, with the A/B ratio
now 1.5 and the A/C ratio unchanged at 12. The
single-variable model based on this scoring demonstrates
no lack of fit when compared with the total counts
model (P=0.74).
Maximum likelihood estimation of the total counts
model gave the coefficient estimates ^  A =2.96, ^  B =1.97
and ^  C =0.15. With a baseline score of 1 assigned to
Grade C, these values suggest that the numerical value
TABLE 1 Demographics of patients recruited into the
study (n=369)
Patient
characteristics Value
Female sex, % 92.7
Age, mean (S.D.), years 41.6 (13.2)
Race, %
Caucasian 59.9
Afro-Caribbean 18.4
South Asian 18.4
Oriental 1.4
Others 1.9
Disease duration, mean (S.D.), years 8.8 (7.7)
Number of assessments, %
1 11.4
2 12.5
3 19.8
4 18.7
5 15.2
6 10.0
57 8.1
FIG.1Histograms showing the distribution of the esti-
mated ratio for (A) a Grade A to a Grade B, (B) a Grade A
to a Grade C for the BILAG-2004 index.
TABLE 2 Summary of the BILAG-2004 index scores at
each assessment, by change in therapy (n=1510)
Scoring characteristics
of visits
Increase in
therapy
No increase
in therapy
No. of visits with 51
Grade A (%)
69 (76.7) 21 (23.3)
No. of visits with 51 Grade B
and 0 Grade A (%)
207 (52.9) 184 (47.1)
No. of visits with 51 Grade C, 0
Grade B and 0 Grade A (%)
62 (8.5) 666 (91.5)
No. of visits with just Grades D
or E recorded (%)
4 (1.3) 297 (98.7)
Total 342 1168
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Numerical scoring for the BILAG-2004 indexfor Grade A could be  2.96/0.15=19.7, and the numerical
value for Grade B could be  1.97/0.15=13.1. Therefore,
an alternative scoring scheme of A=20, B=13, C=1 and
D/E=0 would also fit the data well but to retain maximum
consistency with the Classic BILAG index scoring, while
retaining a good fit to the data, the A=12, B=8, C=1 and
D/E=0 coding is recommended.
Discussion
This study has determined empirically an additive numer-
ical coding scheme for the BILAG-2004 index using data
from clinical practice. A simple modification of the recom-
mended Classic BILAG index coding [5] (A=12, B=8,
C=1 and D/E=0) was found to be acceptable.
The results indicate that numerical coding schemes
suggested for the Classic BILAG index (A=12, B=5,
C=1, D/E=0 and A=9, B=3, C=1, D/E=0) should not
be used with the BILAG-2004 index. Apart from the dif-
ference in the number of systems (nine in BILAG-2004 and
eight in Classic BILAG), the changes to the items, glossary
and scoring scheme during the development of the
BILAG-2004 index have made it operationally different
from the Classic BILAG index. These changes have
made Grades A and B much more difficult to achieve
and, simultaneously, resulted in Grade C being much
less likely to be treated.
Before this analysis, the Haematological scoring
scheme was changed as it was noted during initial analy-
sis that Haematological Grades A and B did not indepen-
dently predict an increase in therapy. It was subsequently
found that Grades A and B cut-off values for leucopenia
and neutropenia and anaemia were too high as many of
these manifestations of lupus were rarely treated. As a
result, the cut-off values for leucopenia/neutropenia and
anaemia for Grades A and B were revised downwards and
greater emphasis was put on haemolytic anaemia in
determining Grades A and B. These changes are in line
with clinical practice.
One limitation of this study is the cross-sectional
design, whereby only the disease activity at the time of
assessment is considered, although patients did contrib-
ute multiple observations over time. No allowance was
made for other factors linked to treatment decisions,
such as prior disease activity, current therapy, previous
therapy (and its response), presence of comorbidities
and patient’s opinion (in particular, refusal to change
therapy as advised). Furthermore, the data used
did not encompass a full range of possible scores.
Nevertheless, the data are representative of routine clinical
practice. Other limitations to this analysis are as described
for the derivation of the numerical scoring for the Classic
BILAG index [5], and hence will not be repeated here.
The BILAG-2004 index provides system-specific infor-
mation and there will be loss of information if nine ordinal
system scores are combined into a single numerical value.
Therefore, there are many circumstances in which the use
of a single score will be inappropriate and the ordinal
system scores are preferable. However, where a single
summary numerical measure is required, such as asses-
sing laboratory data, comparison with global score indices
and for area under the curve analysis, the coding scheme
of A=12, B=8, C=1 and D/E=0 achieves this
reasonably.
Rheumatology key messages
. An additive numerical scoring scheme for
the BILAG-2004 index is A=12, B=8, C=1 and
D/E=0.
. Numerical coding schemes for the Classic BILAG
index are not appropriate for the BILAG-2004 index.
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